{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T01:14:01Z","timestamp":1768871641240,"version":"3.49.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.ijcard.2018.05.124","type":"journal-article","created":{"date-parts":[[2018,6,2]],"date-time":"2018-06-02T01:42:41Z","timestamp":1527903761000},"page":"179-185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction"],"prefix":"10.1016","volume":"281","author":[{"given":"Kieran F.","family":"Docherty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2018.05.124_bb0005","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","author":"The CONSENSUS Trial Study Group","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0010","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"The SOLVD Investigators","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0015","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0020","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2018.05.124_bb0025","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2018.05.124_bb0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(05)74355-5","article-title":"The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial","volume":"353","author":"Dargie","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2018.05.124_bb0035","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL randomised intervention trial in congestive heart failure (MERIT-HF)","volume":"353","author":"MERIT-HF Study Group","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2018.05.124_bb0040","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0045","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0050","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0055","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0060","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa013474","article-title":"Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction","volume":"346","author":"Moss","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0065","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa032423","article-title":"Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure","volume":"350","author":"Bristow","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0070","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa043399","article-title":"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure","volume":"352","author":"Bardy","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0075","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMoa050496","article-title":"The effect of cardiac resynchronization on morbidity and mortality in heart failure","volume":"352","author":"Cleland","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0080","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","article-title":"Cardiac-resynchronization therapy for the prevention of heart-failure events","volume":"361","author":"Moss","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0085","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1009540","article-title":"Cardiac-resynchronization therapy for mild-to-moderate heart failure","volume":"363","author":"Arnold","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0090","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2018.05.124_bb0095","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","article-title":"Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals","volume":"391","author":"Conrad","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2018.05.124_bb0100","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0105","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0024-3205(81)90370-2","article-title":"A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats","volume":"28","author":"de Bold","year":"1981","journal-title":"Life Sci."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0110","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.jacc.2007.09.021","article-title":"Natriuretic peptides","volume":"50","author":"Daniels","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0115","first-page":"1531","article-title":"Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial","volume":"287","author":"Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF)","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2018.05.124_bb0120","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1100171","article-title":"Effect of nesiritide in patients with acute decompensated heart failure","volume":"365","author":"O'Connor","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0125","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1253\/circj.CJ-08-0130","article-title":"Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study","volume":"72","author":"Hata","year":"2008","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0130","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1056\/NEJMoa1601895","article-title":"Effect of ularitide on cardiovascular mortality in acute heart failure","volume":"376","author":"Packer","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0135","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1111\/j.1742-4658.2011.08082.x","article-title":"Natriuretic peptide metabolism, clearance and degradation","volume":"278","author":"Potter","year":"2015","journal-title":"FEBS J."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0140","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1042\/bj1370477","article-title":"The purification and specificity of a neutral endopeptidase from rabbit kidney brush border","volume":"137","author":"Kerr","year":"1974","journal-title":"Biochem. J."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0145","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jacc.2016.04.060","article-title":"A test in context: neprilysin: function, inhibition, and biomarker","volume":"68","author":"Bayes-Genis","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0150","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/cbic.201600244","article-title":"The metalloprotease neprilysin degrades and inactivates apelin peptides","volume":"17","author":"McKinnie","year":"2016","journal-title":"ChemBioChem"},{"key":"10.1016\/j.ijcard.2018.05.124_bb0155","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1007\/s00125-005-1847-7","article-title":"Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig","volume":"48","author":"Plamboeck","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.ijcard.2018.05.124_bb0160","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00125-016-4172-4","article-title":"Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels","volume":"60","author":"Willard","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.ijcard.2018.05.124_bb0165","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0022-3565(25)22255-8","article-title":"SCH 39370, a neutral metalloendopeptidase inhibitor, potentiates biological responses to atrial natriuretic factor and lowers blood pressure in desoxycorticosterone acetate-sodium hypertensive rats","volume":"250","author":"Sybertz","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0170","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/288286a0","article-title":"The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice","volume":"288","author":"Roques","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.ijcard.2018.05.124_bb0175","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1042\/cs0800265","article-title":"Inhibition of neutral endopeptidase (EC 3.4.24.11) leads to an atrial natriuretic factor-mediated natriuretic, diuretic and antihypertensive response in rodents","volume":"80","author":"Shepperson","year":"1991","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.ijcard.2018.05.124_bb0180","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/0140-6736(90)90595-V","article-title":"Effect of sinorphan on plasma atrial natriuretic factor in congestive heart failure","volume":"335","author":"Kahn","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2018.05.124_bb0185","doi-asserted-by":"crossref","first-page":"7580","DOI":"10.1073\/pnas.86.19.7580","article-title":"Protection of atrial natriuretic factor against degradation: diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3.4.24.11) by acetorphan","volume":"86","author":"Gros","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0190","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0140-6736(89)90714-9","article-title":"Effect of UK 69 578: a novel atriopeptidase inhibitor","volume":"334","author":"Northridge","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2018.05.124_bb0195","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0002-8703(99)70082-7","article-title":"Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure","volume":"138","author":"Northridge","year":"1999","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0200","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/00004872-199207000-00002","article-title":"Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension","volume":"10","author":"Bevan","year":"1992","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0205","series-title":"The Effect of the Neutral Endopeptidase Inhibitor Drug, Candoxatril, on Circulating Levels of Two of the Most Potent Vasoactive Peptides","author":"McDowell","year":"1997"},{"key":"10.1016\/j.ijcard.2018.05.124_bb0210","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1161\/01.CIR.97.23.2323","article-title":"Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo","volume":"97","author":"Ferro","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.05.124_bb0215","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/1755-5922.12053","article-title":"Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat","volume":"32","author":"Dalzell","year":"2014","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0220","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1021\/jm00034a005","article-title":"New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension","volume":"37","author":"Fourni\u00e9-Zaluski","year":"1994","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0225","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/00005344-199103000-00015","article-title":"Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme","volume":"17","author":"Seymour","year":"1991","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0230","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1021\/jm970041e","article-title":"Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase","volume":"40","author":"Robl","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0235","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(00)02602-7","article-title":"Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial","volume":"356","author":"Rouleau","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2018.05.124_bb0240","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2018.05.124_bb0245","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ijcard.2018.05.124_bb0250","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/sj.bjp.0707641","article-title":"Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema","volume":"153","author":"Fryer","year":"2009","journal-title":"Br. J. Pharmacol."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527318319892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527318319892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T23:12:53Z","timestamp":1751670773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527318319892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":50,"alternative-id":["S0167527318319892"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2018.05.124","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiotensin receptor-neprilysin inhibitors: A new paradigm in heart failure with reduced ejection fraction","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2018.05.124","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}